Melanoma Clinical Trial
IL-2 “SELECT” Tissue Collection Protocol in Patients With Advanced Melanoma
The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information (for example; cancer diagnosis and history, prior treatments for cancer, etc.) blood and tumor samples prior to treatment and tumor measurements after treatment.
Original tumor slides will be collected to identify tumor markers that may predict responses to treatment. Blood samples will be obtained prior to treatment with IL-2.
Malignant melanoma that is metastatic or unresectable
Eligible to receive high-dose IL-2
Tissue block available with adequate tumor to perform RNA extraction and DASL analysis
Prior immunotherapy for unresectable or metastatic disease
Untreated brain metastases, leptomeningeal disease, or seizure disorder
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Boston Massachusetts, 02215, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.